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ABSTRACT
Objective To generate evidence on the longer term cost
effectivenessof disease modifying treatmentsin patients
with relapsing-remitting multiple sclerosis.
Design Prospective cohort study with historical
comparator.
Setting Specialist multiple sclerosis clinics in 70 centres
in the United Kingdom.
Participants Patients with relapsing-remitting multiple
sclerosis who started treatment from May 2002 to April
2005 under the UK risk sharing scheme.
InterventionsTreatmentwithinterferonbetaorglatiramer
acetate in accordance with guidelines of the UK
Association of British Neurologists.
Main outcome measures Observed utility weighted
progression in disability at two years’ follow-up assessed
on the expanded disability statusscale (EDSS) compared
with that expected by applying the progression rates in a
comparator dataset, modified for patients receiving
treatment by multiplying by the hazard ratio derived
separately for each disease modifying treatment from the
randomised trials.
Results In the primary per protocol analysis, progression
in disability was worse than that predicted and worse
than that in the untreated comparator dataset (“deviation
score” of 113%; excess in mean disability status scale
0.28). In sensitivity analyses, however, the deviation
score varied from −72% (using raw baseline disability
status scale scores, rather than applying a “no
improvement”algorithm)to156%(imputingmissingdata
for year two from progression rates for year one).
Conclusions It is too early to reach any conclusion about
the cost effectiveness of disease modifying treatments
from this first interim analysis. Important methodological
issues, including the need for additional comparator
datasets, the potential bias from missing data, and the
impact of the “no improvement” rule, will need to be
addressed and long term follow-up of all patients is
essentialtosecuremeaningfulresults.Futureanalysesof
the cohort are likely to be more informative, not least
because they will be less sensitive to short term
fluctuations in disability.
INTRODUCTION
In January 2002, the National Institute for Health and
Clinical Excellence (NICE) published appraisal gui-
dance on the use of disease modifying treatments for
multiple sclerosis.
1 The drugs assessed were the beta
interferons (Avonex, Betaferon, Rebif 22 μg, Rebif 44
μg) and glatiramer acetate (Copaxone). Randomised
placebocontrolledtrialshadshowntheshorttermclin-
ical effectiveness of each drug. To determine the cost
utility of the long term effects of these treatments
ScHARR (Sheffield School of Health and Related
Research) created an economic model
2 using data on
quality of life collected by the MS Trust from patients
intheUnitedKingdom,
3costdatafromKobeltetal,
4a
natural history dataset from London, Ontario,
5 and
estimates of delay in disease progression derived
from randomised controlled trials. This model sug-
gested that the disease modifying treatments were not
cost effective over a 10 or 15 year horizon but became
more cost effective over 20 years. It was uncertain,
however,whethertheresultsofrandomisedcontrolled
trialslastingnomorethanthreeyearscouldbereliably
extrapolatedoveralongerperiodandwhetherpatients
who stopped treatment retained any benefits beyond
that point, with disease progressing in line with that
expected for untreated patients, or whether there was
a rebound effect after cessation of treatment.
Given the above uncertainties, NICE was unable to
recommend the treatments for use in the NHS at cur-
rent prices but, instead, invited the Department of
Health and the National Assembly for Wales to con-
siderhowtheycouldbemadeavailabletopatientsina
cost effective manner.
1 In February 2002 the UK
health departments set out the agreed basis of a “risk
sharingscheme,”whichwouldallowtheprescribingof
Avonex, Betaferon, Copaxone, and Rebif 22 and 44
according to the Association of British Neurologists’
2001 guidelines,
6 conditional on the development of a
10yearmonitoringstudythatwouldcollectdataonthe
progressionofdiseasein treatedpatientsandthushelp
to assess the two critical uncertainties emphasised by
NICE.Ifanyindividualproductfailedtoshowbenefits
consistent with projections made at the outset of the
scheme, with the ScHARR model, the subsequent
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effectiveness to a benchmark of £36000 per quality
adjusted life year (QALY) evaluated over a 20 year
horizon. The choice of treatment was at the discretion
of the neurologist in consultation with the patient. We
report the results and implications of the first planned
interimanalysis,carriedoutwhenallpatientshadbeen
in the scheme for at least two years.
METHODS
The broad principles for the establishment and con-
ductofthe risk sharingschemewere setout in anNHS
circular.
7 The first patients who consented to take part
inthestudystartedtreatmentwithintwomonthsofthe
publication of the circular. A steering committee was
set up with representation from the parties to the
scheme—that is, the health departments in England,
Wales,Scotland,andNorthernIreland,eachmanufac-
turer,theMSTrust,theMSSociety,theAssociationof
British Neurologists, the Royal College of Nursing,
and the UK MS Nurse Specialist Association.
The MS Trust acts as the secretariat to the scheme
andcustodianofthedata.Twoclinicalneurologyleads
(JP, MB) provide clinical advice on the conduct of the
studyandliaisewithotherclinicians.Forthethreeyear
recruitment phase ScHARR coordinated the data col-
lection and developed proposals for the statistical ana-
lysisinlinewiththeprinciplessetoutinthecircular.In
2006 a clinical research organisation (Parexel) took
over data collection and statistical analysis, overseen
by an independent scientific advisory group. The
MS Trust, the MS Society, Parexel, the Department
of Health, the four pharmaceutical companies, and
theclinicalleadsattendscientificadvisorygroupmeet-
ings (as observers). The remit of the group is to advise
on scientific aspects of the study design, data analysis,
and data interpretation and to assess additional study
proposals; in particular, the scientific advisory group
was responsible for advising on a detailed statistical
analysis plan, amplifying the description of the
plannedprimaryanalysisintheoriginalhealthservices
circular.
Recruitment of patients
The circular suggested that 5000-7000 patients should
be recruited to a monitoring cohort to allow about
1000 patients taking each treatment. Exploratory cal-
culations suggested that this would be large enough to
reduce sampling errors to an acceptable level. The
5583 patients assessed by clinicians as meeting the cri-
teria of the Association of British Neurologists
(broadly, patients with relapses as the predominant
aspect of disease) were recruited into the monitoring
studyfromMay2002toApril2005from70neurology
centresacrosstheUK.Thisrisksharingschemecohort
represents about 80% of patients with multiple sclero-
sis starting treatment in the UK over this period.
Patients who entered the scheme with a diagnosis of
secondary progressive multiple sclerosis were ana-
lysedseparately.Themainanalysesinthispaperrelate
to the 4749 patients with relapsing-remitting multiple
sclerosis at entry.
Data collection
As this was a pragmatic study undertaken within rou-
tine practice, it wasdesigned to collect minimum basic
information through clinical assessments with
expanded disability status scale (EDSS) scores
8 per-
formed annually within a three month window of the
entry date into the study. Patients were to be followed
even if treatment was stopped or altered to minimise
“dropoutbias”andtotesttheScHARRmodelassump-
tionsthatbenefituptothatpointismaintainedoverthe
longer term.
Outcome measures
Withnorandomisedcontrolgroup,wehadtocompare
thediseaseprogressionfortherisksharingcohortwith
a cohort of patients who were recruited and followed
up before the routine use of disease modifying treat-
ments. For the purposes both of the original ScHARR
model and of the risk sharing scheme, the London,
Ontario, dataset was considered to be the largest,
most complete population based source of such data.
5
This dataset consists of 1043 Canadian patients,
recruited in 1972-84, whose disability was assessed
about annually for a median of 25 years from onset of
disease with the disability status scale (DSS, the prede-
cessoroftheEDSS).Asintherisksharingcohort,inthe
Ontario dataset diagnoses were made by experienced
neurologists according to standard clinical criteria.
9
Although patients in this cohort were followed largely
prospectively, the dataset derived from this seems to
have been collated retrospectively with the disability
status scores smoothedto eliminate short term fluctua-
tions.As a result thereare no “regressions”in EDSSin
the Ontario dataset; disability scores for individual
patients can only worsen over time and the ScHARR
model had to reflect this.
For each treatmentseparately we used the ScHARR
model to predict the expected movement of patients
between the EDSS states both “on” and “off” treat-
ment. For patients “off” treatment, the ScHARR
model uses a matrix of transition probabilities derived
from the actual progressions seen in the Ontario data-
set (using a subset of 314 patients who were judged to
have fulfilled the Association of British Neurologists’
criteria—experiencingtwoormorerelapsesinthepre-
vious two years—at baseline). These transition
matrices are modified for patients “on” treatment by
multiplyingby the hazardratio (relative rateof disease
progression) derived separately for each treatment
from the pivotal trials. The model then predicts how
the distribution of patients will evolve over a 20 year
horizon,startingwiththeactualdistributionatbaseline
fortheappropriatesubsetofpatientsintherisksharing
scheme cohort. As in SchARR’s original work for the
NICE appraisal, we assumed that patients who stop
taking treatment will experience the same rate of dis-
easeprogressionfromthatpointonwardsaspatientsat
the same EDSS point who have never been treated.
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score of the average observed loss of utility (average
utilityweighteddiseaseprogression;seeappendix1on
bmj.com) for patients in the risk sharing scheme com-
pared with the expected loss calculated by the
ScHARR model for patients “on” treatment. Utilities
were derived from a two stage survey of 1554 respon-
dents from the MS Trust database (78% response rate
to second questionnaire, 18% of total database) who
completed the EQ-5D, which was then converted to a
single utility, the EQ-5D index score.
3
We calculated the primary outcome from several
other measures. The “expected benefit” of treatment
(with a specific treatment) is the “hypothetical” differ-
ence between the expected outcome without and with
treatment,ascalculatedineachcasefromtheScHARR
model. The “actual benefit” of treatment is the
“observed” difference between the expected outcome
without treatment and the actual outcome with treat-
ment. The “deviation” of the actual benefit from the
expected is calculated as a percentage of the expected
benefit. This measure can have negative or positive
values so that a negative deviation implies that the
observedbenefitwasgreater thanpredicted,a positive
deviation implies that it was worse than predicted, and
a value of 0 indicates that it was exactly as predicted.
This deviation measure is calculated every two years
and used as the basis of possible price adjustments
under the agreed rules of the scheme; thus if the short-
fall between actual and expected benefit exceeds an
agreed “tolerance margin” (20% at year two, 10% at
subsequent review points) the Department of Health
and relevant manufacturer will renegotiate the current
priceforthetreatmentsothatitachievescosteffective-
nessat£36000withthenewestimatedtreatmenteffect.
We have also reported changes in the average
(unweighted) EDSS score, comparing the expected
and actual change from baseline, as this will be more
familiar and easier to conceptualise.
Statistical methods
The primary analysis plan made maximum use of the
availabledata,includingdataonpatientswithonlyone
year of valid follow-up. For this subset, comparison is
with the expected progression over one year as calcu-
lated by the ScHARR model.
One major assumption of the ScHARR model (fol-
lowing the conventions of the Ontario dataset) is that
EDSS scores are constrained to remain stable or wor-
sen and improvements are not possible. We therefore
had to apply an algorithm to the risk sharing scheme
cohorttomodelascloselyaspossiblethewayinwhich
we understand the Ontario dataset to have been com-
piled (we did not have access to the raw Ontario data).
This algorithm (see appendix 2 on bmj.com) includes,
for some patients, a (downwards) adjustment to the
baseline EDSS score where the “raw” data would
otherwisehaveimpliedanimprovementfrombaseline
to year one or in subsequent years. In addition, the
algorithm means that an apparent disease progression
to year two, for example, is disregarded if it is not
confirmedbythedataforyearthree.Formanypatients
intheanalysisdatasetfortherisksharingscheme,how-
ever, three year assessments are not yet available and
so, in the primary analyses, we accepted unconfirmed
disease progressions at this stage, even though further
follow-up might modify these.
The primary (per protocol) analysis censored
patients who died from causes other than multiple
sclerosis,emigrated,werelosttofollow-up,orswitched
treatments. Patients who died from a cause related to
multiple sclerosis had their subsequent missing EDSS
score altered to a value of 10. The ScHARR model
assumed that all those who progressed to secondary
progressive multiple sclerosis would stop treatment
and could be treated in the same way as other patients
whostoppedtreatment(thatis,assumingthesamerate
of disease progression as untreated patients). Patients
who moved from relapsing-remitting multiple sclero-
sistosecondaryprogressivemultiplesclerosisbutwho
still took treatment (regardless of whether the treat-
ment was actually licensed for use in secondary pro-
gressive multiple sclerosis or not) were censored after
the first assessment after conversion and were then
treated as “lost to follow-up” because in the original
scheme we did not expect that there would be many
such patients and had not defined a clear basis for esti-
matingtheir“expected”diseaseprogression.Wehave,
however, carried out a sensitivity analysis to include
these patients.
The scientific advisory group recognised that some
oftheexclusionsorcensoringwouldprobablybiasthe
progression data. Also, at this early stage, the results
could be unduly influenced by a small number of
patientswithextremechangesinEDSSscore(ineither
direction). The scientific advisory group, therefore,
suggested several supplementary sensitivity analyses
(table 1). Some of these were specified in advance,
others in the light of unexpected features in the year
two data.
RESULTS
Participants
Out of 5583 patients registered into the monitoring
scheme, 4749 (85%) had relapsing-remitting multiple
sclerosis. Of these, 208 (4.4%) were ineligible for ana-
lysis and we excluded 248 (5.2%) because they were
never treated or did not start treatment within three
months of baseline assessment (fig 1). Of the 4293
who were eligible and treated, 358 (8.3%) had no sub-
sequent follow-up data and a further 249 (5.8%) had
data that were not used in the primaryanalysis,mostly
becausethepatienthadswitchedtreatmentorhadcon-
verted to secondary progressive multiple sclerosis in
the previous year and remained taking treatment
(fig 1). Thus 3686 (85.9%) of eligible and treated
patients had at least some valid follow-up data. These
3686 patients are referred to as the “per protocol ana-
lysis cohort.” Of these, 2901/4293 (67.6%) had valid
EDSS assessments at year two and 785 patients had
valid EDSS assessment at year one but not at year
two. Of the 2850 patients who were still relapsing-
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2609 (91.5%) were still receiving their original disease
modifying treatment. An additional 228 patients with
relapsing-remitting multiple sclerosis had switched
treatment before their first available assessment.
Patients converting to secondary progressive multiple
sclerosis who stopped treatment were included in the
per protocol cohort, but, by the end of the two year
period,only48(12.0%)of401patientswhoprogressed
tosecondaryprogressivemultiplesclerosishaddiscon-
tinued treatment by their next annual assessment.
Table 2showsthe baselinedata characteristics ofall
the eligible patients with relapsing-remitting multiple
sclerosis at baseline and the subset used in the primary
analysis. The age and sex distributions, the baseline
EDSS values, previous relapse rates, and times from
symptom onset and diagnosis are almost identical for
thetwogroups.Acomparisonwithdataforthepatients
with secondary progressive multiple sclerosis at base-
line shows that, as expected, the latter have higher
baselineEDSSvaluesandalongertimefromsymptom
onset and diagnosis (data not shown).
Over the two year period 1403 (38%) patients in the
per protocol analysis set showed an improvement in
EDSS scores, and for 591 patients (16%) this was con-
firmed either up to year two or at the next annual
assessment. These proportions are in contrast with
the assumption in the ScHARR model, based on the
Ontario dataset, that improvements (especially sus-
tained improvements) in annual scores are unlikely.
Over the same period 1803 (49%) patients had dete-
rioration in EDSS, and in 834 (23%) this was con-
firmed. At year two, 2629 patients (71.3% of patients
in the per protocol analysis cohort) were still taking
their initial treatment, but 272 (7.4%) had stopped all
treatment, 214 (5.8%) had switched to a different dis-
ease modifying treatment, and 571 (15.5%) had
become lost to follow-up, died, or had missing EDSS
data at year two. For the per protocol analysis fig 2
shows a comparison of expected and actual EDSS at
follow-up.
ThemeanannualrateofchangeintheEDSSscorein
the perprotocol analysiscohort was0.35 afterapplica-
tion of the “no improvement” rules and 0.16 with the
“raw”data. As a result of the no improvementrules, of
the 3686 patients in the per protocol analysis cohort,
we modified EDSS scores of 989 (26.8%) patients at
Table 1 |List of sensitivity analyses undertaken with rationale
Problem to be addressed Sensitivity analysis
Patients switching treatment might have particularly poor outcomes so excluding them might
bias results
Calculate on “intent to treat” basis, retaining all such patients in analysis
Patients converting from RRMS to SPMS but remaining on DMTs might have particularly
aggressive disease, so excluding them might bias results
Retain patients in analysis after developing SPMS and still taking DMTs; calculate “expected”
benefitonassumptionthatDMTsmodifynaturalrateofdiseaseprogressionbysamefactoras
shown for RRMS in randomised controlled trials*
Results might be distorted by small number of outliers Exclude patients with 1% most extreme movement (up or down) in EDSS score
Bias because of lack of year three data for some patients needed to confirm apparent
progression at year two
Limit analysis to subset of patients with data for year three
Bias because of lack of year three data for some patients needed to confirm apparent
progression at year two
Use all available data to estimate proportion of apparent progressions subsequently
confirmed and apply this to patients with apparent progression at year two but no year three
data*
Possible bias because of missing year two data (see below) Perform “best case/worst case” analysis to impute missing year two values—for “best case”
assume no further disease progression after year one, for “worst case” extrapolate from
progression between baseline and year one
Possible bias because of retrospective adjustment of baseline data for some patients Leave baseline EDSS values unadjusted while continuing to apply “smoothing” algorithm to
subsequent data points
RRMS=relapsing-remitting multiple sclerosis; SPMS=secondary progressive multiple sclerosis; DMTs=disease modifying treatments; EDSS=expanded disability status scale.
*Pre-specified analysis
Valid year 1 data only (n=785, 18.3%),
(n=765, 97.5%) still taking DMT
Valid year 2 data (n=2901, 67.6%),
(n=2609, 91.5%) still taking DMT
Patients with confirmed
year 2 EDSS scores
(n=1479, 34.5%)
Missing year 2 EDSS (n=463):
  Non-MS death (n=1)
  MS death in year 1 (n=1)
  Emigrated (n=2)
  No year 2 EDSS (n=457)
  Lost to follow-up/withdrew
    from study (n=2)
Non-valid year 2 EDSS (n=322):
  Switched DMT in year 2,
    still RRMS* (n=174)
  Converted to SPMS in year 1,
    on initial DMT at year 2*† (n=134)
  Converted to SPMS in year 1
    switched DMT in year 2*† (n=14)
All identified patients (n=5583)
Eligible and treated RRMS at baseline (n=4293, 100%)
Patients with any valid data after baseline (per protocol cohort) (n=3686, 85.9%)
Not RRMS (n=834, 779 SPMS, 55 unknown)
Ineligible (n=208): 
  Not fulfilling ABN criteria (n=7)
  No baseline EDSS (n=5)
  Already receiving treatment (n=102)
  Entered after close of recruitment (n=7)
  Other reasons (n=87)
Eligible but not treated (n=248)
Missing EDSS after baseline (n=358):
  Emigrated (n=8)
  No year 1 or year 2 EDSS (n=348)
  Lost to follow-up or withdrew from study (n=2)
No valid EDSS after baseline (n=249):
  Switched DMT before first available assessment, still RRMS* (n=228)
  Other (n=21)
Fig 1 | Participants with relapsing-remitting multiple sclerosis (RRMS) taking disease modifying
treatments (DMT) in multiple sclerosis risk sharing scheme. *Data used for supplementary
analyses. †Patients assessed as secondary progressive multiple sclerosis (SPMS) at year 1
follow-up; their EDSS scores for year 1 (but not for later years) retained in primary analysis
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low-up visit.
The baseline EDSS and mean change per year for
the primary outcome cohort compared with those
patients who have only one year of valid follow-up
data show that the latter subgroup were more disabled
at baseline and progressed more rapidly. Thus mean
EDSSforthe2901patientsintheperprotocolanalysis
with valid EDSS data at year two was 2.68 at baseline,
2.90 after one year, and 3.24 after two years. Patients
whohadonlyoneyearofvaliddata (n=785) hadmean
EDSS of 3.14 at baseline and 3.77 after one year
(P<0.001 for comparison of baseline and of rate of
change, Mann-Whitney-Wilcoxon test).
Primary analysis
Theprimaryanalysisshowsapositivedeviationscoreof
113% for the weighted utility score, the primary out-
come measure (table 3). At face value this indicates
that cost effectiveness of disease modifying treatments
wasworsethanthatexpectedfromtheScHARRmodel
as applied to the Ontario dataset and also worse than
that predicted with no treatment from the same model.
In absolute terms the EDSS score was 0.10 unit worse
than the control data and 0.28 units worse than pre-
dicted on the assumption that the disease modifying
treatments delay progression of the disease.
Sensitivity analyses
Retaining all patients in the analysis regardless of any
switching between treatments, and retaining patients
who moved from relapsing-remitting to secondary
progressive multiple sclerosis but remained taking
treatment, made virtually no difference to the devia-
tion measure. The difference between observed and
expected EDSS progression was less marked when
we restricted the analysis to the subgroup of patients
with the year two EDSS score confirmed by valid
year three data (0.14 v 0.28) or when we adjusted the
results to take account of the expected proportion of
apparent progressions at year two that were not subse-
quently confirmed at year three (0.19 v 0.28). Imputa-
tion of data for year two in patients with only year one
values gave results marginally more favourable to the
disease modifying treatments in the “best case” sce-
nario (0.27) but distinctly worse in the “worst case”
scenario (0.33) compared with the primary analysis
(0.28). When we used the unadjusted EDSS scores at
baseline(therebyallowingimprovementfrombaseline
to year one) while continuing to apply the “no
improvement” algorithm to subsequent data points,
however, there was a negative deviation measure
(−84)—that is, patients progressed less rapidly than
predicted from the ScHARR model (−0.11 EDSS
pointscomparedwith0.28intheperprotocolanalysis)
(fig 3).
DISCUSSION
In this observational cohort study of a risk sharing
scheme for disease modifying treatments in patients
with multiple sclerosis we found no evidence that
these treatments are cost effective. The purpose of the
scheme is to provide patients with access to treatments
and at the same time collect evidence to help to assess
their cost effectiveness in a standard NHS setting for
future pricing negotiations.
The outcomes so far obtained in the pre-specified
primary analysis suggest a lack of delay in disease pro-
gression for all disease modifying treatments com-
bined. Some of the sensitivity analyses performed
were more favourable to the drugs, with one even
implying better outcomes than expected on the
ScHARR model, although one (the “worst case” ver-
sionof the analysisaddressingpossiblebiasbecause of
missingyeartwodata)gavelessfavourableresultsthan
the primary analysis, suggesting a bias in favour of
treatment resulting from missing data.
Table 2 |Baseline characteristics of all eligible and treated patients with relapsing-remitting multiple sclerosis (RRMS) at
entry and those included in per protocol analysis cohort
Characteristic
All eligible and treated patients with
RRMS at entry (n=4293*)
Per protocol analysis cohort
(n=3686†)
No (%) of men 1060 (24.7) 906 (24.6)
No (%) of women 3233 (75.3) 2780 (75.4)
Median (range) age (years) 38 (18-73) 38 (18-73)
Mean (SD, range) EDSS 3.07 (1.52, 0.0-6.5) 3.05 (1.52, 0-6.5)
Median (range) time since symptom onset (years) 5.7 (0-48) 5.7 (0-48)
Median (range) time since first diagnosis (years) 2.6 (0-41) 2.6 (0-41)
Median (range) No of confirmed relapses in last 2 years 3 (0-21) 3 (0-21)
*Missing data: 5 for age, 20 for symptom onset, 41 for time since diagnosis, 3 for previous relapses.
†Missing data: 5 for age, 16 for symptom onset, 36 for time since diagnosis, 2 for previous relapses.
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P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
(
%
)
0 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10
0
4
8
12
16
20
Baseline
Expected with treatment
Actual
Fig 2 | Expected and observed EDSS at follow-up for per protocol analysis
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Our use of the no improvement “rules” might have
underestimated the effects of treatment. As already
noted,theScHARRmodeldoesnotpermitregressions
(that is, improvement in disability) and the data from
the risk sharing scheme had to be modified to allow
comparison with the predicted disease progression.
EDSS scores for patients with multiple sclerosis, how-
ever, do spontaneously improve for various reasons:
recovery from relapse, natural fluctuations, and mea-
surement error. In addition, it is clear that the disease
modifying treatments do reduce relapses
10 and might
allow improved recovery from relapse early in treat-
ment. In the risk sharing cohort, 32% of patients show
some improvement in disability scores and for 14%
this improvement is sustained for a second year.
TomaintaincomparabilitywiththeOntariodataset,
we did not use the rawEDSS scoresas thiswould have
biasedthedeviancescoretooverestimatethetrueben-
efits of treatment. It is less clear whether the primary
analysis is correct in applying the no improvement
algorithm to adjust the baseline score as well as the
subsequent scores; using the unadjusted baseline
values had a marked effect on the results. The impact
of the “no improvement” assumption will diminish
with longer follow-up as patients will show greater
change in their EDSS scores and the effects of any
minor misclassifications early in follow-up will be of
less significance, but it will remain a source of some
uncertainty in estimating cost effectiveness.
The Ontariocomparatordataset mightnot beappro-
priateforotherreasons,suchasthenaturalcourseofthe
diseasechangingovertime.Thiswouldbeavalidexpla-
nation only if patients progressed more rapidly today
than20yearsago.Datasuggestthatpatientswithmulti-
plesclerosisnowprogressmoreslowly,
11socomparison
with historical data should overestimate the potential
benefits of treatment. Compared with the primary out-
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Fig 3 | Effect of baseline adjustment of EDSS
Table 3 |Primary outcome and sensitivity analyses with EDSS and deviation score
Predicted progression from transition probabilities
Actual progression
observed with treatment
Difference
(actual less
predicted)
Deviation score
(%) Without treatment With treatment
Per protocol analysis (n= =3686)
EDSS 0.47 0.29 0.57 (0.544 to 0.603) 0.28 —
Utility score 0.0254 0.0158 0.0266 — 113
Including DMT switchers (n= =3931)
EDSS 0.48 0.30 0.59 (0.559 to 0.617) 0.28 —
Utility score 0.0258 0.0162 0.0271 — 113
Including SPMS converters on DMTs (n= =3690)
EDSS 0.48 0.30 0.58 (0.550 to 0.610) 0.27 —
Utility score 0.0261 0.0164 0.0275 — 114
Excluding extreme outliers (n= =3650)
EDSS 0.47 0.30 0.54 (0.514 to 0.570) 0.25 —
Utility score 0.0254 0.0158 0.0250 — 96
Subgroup analysis with year 2 confirmed scores (n= =1479)
EDSS 0.50 0.32 0.46 (0.422 to 0.507) 0.14 —
Utility score 0.0263 0.0162 0.0214 — 51
Predicted change in unconfirmed year 2 scores (n= =3686)
EDSS 0.0.47 0.29 0.48* 0.19 —
Utility score 0.0254 0.0158 0.0225 — 70
Imputing missing year 2 scores— —best case scenario (n= =3686)
EDSS 0.53 0.33 0.60 (0.566 to 0.627) 0.27 —
Utility score 0.0290 0.0179 0.0285 — 95
Imputing missing year 2 scores— —worst case scenario (n= =3686)
EDSS 0.53 0.33 0.66 (0.629 to 0.699) 0.33 —
Utility score 0.0290 0.0179 0.0351 — 156
Unadjusted baseline scores (n= =3686)
EDSS 0.49 0.31 0.20 (0.163 to 0.241) −0.11 —
Utility score 0.0257 0.0157 0.0073 — −84
DMTs=disease modifying treatments; EDSS=expanded disability status scale.
*95% confidence intervals cannot be calculated by standard methods because of indirect method used to estimate mean EDSS change.
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ates, such as age at presentation and sex, that are asso-
ciated with disease progression. We have not explored
this possibility as we do not have access to the raw
Ontario data, but the transition probabilities for the
Ontario cohort were taken for a subgroup of patients
fulfillingtheAssociationofBritishNeurologists’criteria
for inclusion in the multiple sclerosis risk sharing
scheme to make it as comparable as possible.
These uncertainties make reliable interpretation of
the short term results problematic, and we have not
presented data for the individual treatments, which
are likely to be further confounded by selection bias
because disease severity might itself determine which
treatmentisused.Thescientificadvisorygroupconsid-
ered that it was premature, at this stage, to reach any
decisionaboutre-pricingthe drugswithoutfurtherfol-
low-up and analyses.
Limitations and future plans
Estimating cost effectiveness from an observational
cohort study with a historical comparator dataset has
inherent problems that would be avoided in a rando-
mised controlled trial.
12 In 2002, however, a placebo
controlled study lasting for 10 years or more was not
deemed feasible as the safety and efficacy of these pro-
ducts had already been accepted by the regulatory
authorities. In addition, patients would be unwilling
to be randomised to placebo for such a long period,
thedropoutratewouldhavebeenhigh,andsomeclin-
icians who consider that the existing evidence on effi-
cacy is already convincing would have regarded
allocation to placebo as unethical. With hindsight the
inclusion of further sensitivity analyses in pivotal pub-
licationscouldhaveshedadditionallightontheuncer-
tainties about treatments in multiple sclerosis.
1012
We appreciated from the outset that a major limita-
tion was the validity and generalisability of the com-
parison dataset. Consistent results with various
different comparator databases would add confidence
to conclusions about the cost effectiveness of treat-
ment. The scientific advisory group is actively pursu-
ing alternative sources of data on disease progression
in untreated patients. This would have two major ben-
efits. Firstly, it would allow estimates of progression
rates based on unadjusted data where EDSS scores
can get better as well as worse and hence the analysis
canberepeatedontherawratherthanadjustedscores.
Secondly, it would allow examination of whether the
rates of disease progression shown in the Ontario
cohort are similar, at least in the short term, to those
in other cohorts from different geographical as well as
temporal populations of patients.
Some of the patients who entered the risk sharing
scheme (and therefore started disease modifying treat-
ments) at the outset will have had disease for a longer
duration than is current clinical practice, as access to
treatment in the UK was fairly restricted before the
introduction of the scheme. This would potentially
bias the results to underestimate the effects of treat-
ment if (as recent results suggest) such patients show
less benefit than those treated earlier in the natural
course.
13 Another potential bias, which would overes-
timate the benefits of treatment, is incomplete follow-
up. Completeness of follow-up might well differ
between the treated and reference cohorts. As
expected, patients with incomplete follow-up data in
the risk sharing scheme had more rapid disease pro-
gression: one year decline was greater in those with
one year but not two year assessments than in those
who were assessed at both time points. A best case-
worst case analysis suggested that adjustment for this
effectwouldprobablygiveevenlessfavourableresults
than the per protocol analysis. Conversely, when we
applied a correction to allow for some of the year two
progressions not being confirmed by the subsequent
year three results we saw a smaller positive deviation
score. Imputing data might be problematic and bias
caused by loss to follow-up is a major concern in such
a long term study, highlighting the importance of
obtaining data from all patients who took part in the
scheme even if they are no longer receiving treatment.
Clinic assessments are not always possible—for exam-
ple, patients who have reached high disability scores
(EDSS ≥7.0) and stopped treatment because of pro-
gression can have difficulty attending the clinic. For
this reason, an option is being introduced of having a
telephone assessment of EDSS undertaken by a multi-
ple sclerosis nurse. The telephone EDSS by doctors
has been validated in a pan-European study
14 and a
parallel validation study by multiple sclerosis nurses
is currently under way.
One of the uncertainties in the original ScHARR
model was the estimate of costs and utilities. If the
cost of problems related to multiple sclerosis is not
fully captured then the cost effectiveness of treatment
will beunderestimated. Anadditionalstudytocapture
costandutilitydatahasthereforebeenundertakenand
willbereportedonshortlytohelpinformtheyearfour
analysis.
The original analysis plan wrongly assumed that
patients who developed secondary progressive multiple
sclerosis would stop treatment and would thus be mod-
elled using the untreated transition probabilities. Most
such patients in the scheme, however, continued treat-
ments whether or not they were licensed for secondary
progressive multiple sclerosis. There are several possible
reasons. Firstly, all the treatments probably reduce
relapses, whatever the stage of the disease. Secondly,
withdrawal of treatment might be deferred until the clin-
ician and patient are sure that secondary progression has
occurred, which might not be before one or even two
annual cycles of the scheme. Finally, as there are limited
furthertreatmentoptionspatientscanberesistanttowith-
drawal of treatment. Our secondary analysis showed,
perhaps slightly against expectation, that including
patients who developed secondary progressive multiple
sclerosiswhiletakingtreatmentdidnothaveasignificant
impact on the results.
Sincetheonsetoftherisksharingscheme,therehave
been changes in the management ofpatients with mul-
tiple sclerosis. The updated guidelines from the
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15havewidenedthe
eligibility criteria for disease modifying treatments,
though funding has not been agreed with the Depart-
mentofHealth.Thisitselfwillnotimpactontheresults
of the scheme, although it might make it more difficult
to generalise the findings to current practice. With the
licensing of new classes of drug such as natulizamab,
patients whose relapses do not respond to the scheme
drugs (either because they have an aggressive form of
multiple sclerosis or because they have neutralising
antibodies to interferon beta) might be switched to
newernon-schemedrugs.Toavoidbias,itisimportant
that such patients are included in the analysis, even if
only in sensitivity analyses.
Further efforts are being made to trace patients with
missingdataatyeartwo,adisproportionatenumberof
whommighthavestoppedtakingtreatmentbecauseof
more aggressive disease. This includes the treating
clinicians assessing disability by telephone and indivi-
duallyreviewingcasenotesforthosewithmissingdata.
In addition,it would havebeen desirableto have iden-
tified patients who were eligible for the scheme but
chose not to participate or who were recruited but
then decided not to have treatment. It would then
have been possible to user newer statistical methods
that allow less biased estimates of the potential causal
effects from observational data, as has been done with
antiretroviral therapy for HIV progression.
16
Risk sharing schemes
The risk sharing scheme was an innovative solution to
a familiar dilemma in health technology assessment—
the problem of assessing the longer term benefits of
treatments for progressive diseases when, because of
cost considerations and the difficulties in maintaining
largepopulationsinprolongedplacebocontrolledstu-
dies, pivotal clinical trials maintain randomisation for
only a relatively short period compared with the nat-
ural course of the disease.
Theestablishmentoftherisksharingschemefordis-
ease modifying treatments in multiple sclerosis has
allowed thousands of patients to have access to certain
multiple sclerosis drugs, which they might not have
had if the NICE evaluation had been implemented,
andhasbeenthecatalystformajorchangesintheman-
agement of multiple sclerosis, including substantial
increases in the number of centres with specialist
multi-disciplinary teams and in the number of specia-
list nurses. From the perspective of patients, these are
all positive developments. This has been achieved by
use of NHS resources, which would otherwise have
been available for the treatment of other patients.
Whether the gain to patients with multiple sclerosis
exceeds the loss to those unidentifiable other indivi-
duals remains unresolved.
Other benefits include the establishment of a large
cohortofpatientsthatcouldbeusedforsupplementary
studies on risk factors for disease progression, the
development of expertise at over 70 special multiple
sclerosis treatment centres, and increased funding for
specialist nurses so that now over 200 are employed
compared with 75 at the start of the scheme. While
acknowledging these indirect effects of the establish-
ment of the risk sharing scheme, it should be noted
that the direct costs of running the scheme over a
10 year period will represent only around 1% of the
costs to the NHS of the disease modifying treatments
over this period.
A unique element of this scheme was that the
Department of Health and drug companies negotiated
a reduction in price of some treatments at the outset to
achieve what wasthoughtto bethe anticipatedlevel of
cost effectiveness. This practice has been pioneered in
Australia,wherethePharmaceuticalBenefitsAdvisory
Committee often negotiates the price of a drug down-
wards. The Pharmaceutical Price Regulation Scheme
(PPRS),whichgovernsdrugpricingintheUK,hasnot
usedthisapproachinthepast,althoughthemostrecent
revision to the scheme encourages companies to pro-
pose a cost effective price on first launching their pro-
ducts in the UK market, based on the evidence then
available, and allows them to propose a subsequent
price increase in the light of any further evidence on
cost effectiveness.
17
Other forms of “risk sharing” have emerged since
this scheme was established, but most relate to estab-
lishing an “outcomes guarantee”
18 for treatments in
which the benefit to individual patients can be clini-
cally assessed. An example of this is bortezomib (Vel-
cade) for the treatment of relapsed multiple myeloma,
where a “response rebate” scheme was established by
theDepartmentofHealthsothatpatientswhoshowed
no or minimal response are taken off treatment and
drug costs are refunded by the manufacturer.
19
The multiple sclerosis risk sharing scheme could be
better termed as “coverage with evidence develop-
ment,” which has been used in the past few years in
countriessuchastheUnitedStates, Australia,Canada,
and Europe. This provides interim approval for reim-
bursementofatreatment,conditionalonthecollection
of further evidence and review after a specified
period.
20 This process allows patients’ access to pro-
mising new treatments but manages that access in a
coordinated way, generating additional evidence that
is targeted to reduce uncertainties in a much more
structured way than a traditional post-marketing
study.While thissoundsan attractive option,the com-
parison of contemporary observational data with his-
torical cohorts is notoriously problematic. For
example, the rate of progression in the placebo arm
of a screening evaluation of potential neuroprotective
treatments for Parkinson’s disease was significantly
lower than that in the historical reference cohort and
thus placebo treatment met the criteria for being taken
forward as a promising neuroprotectant.
21
Summary
The UK multiple sclerosis risk sharing scheme was an
innovative approach to collect new cost effectiveness
data as part of an observational clinical cohort study.
Thetwoyearresultshighlightmanyofthemethodolo-
gical difficulties of such an approach, including the
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major uncertainties around the interpretation of the
current results. The primary analysis did not meet the
predefinedlevelforcosteffectivenessbut,atthisstage,
we cannot reliably determine whether the current pri-
cing of these drugs represents value for money for the
NHS. Longer term follow-up will reduce some of the
uncertainties arising from short term fluctuations in
disability scores and will provide new empirical evi-
dence to confirm or refute some of the assumptions
made by the NICE committee when considering the
cost effectiveness of disease modifying treatments.
The longer term success of the scheme, however, is
dependent on the hard work and goodwill of many
NHS staff in continuing to collect data on all patients
who were entered into the scheme.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Randomised controlled trials have shown that disease modifying treatments can slow the
progression of relapsing-remitting multiple sclerosis over a two to three year period
It is not known whether these benefits persist over the longer term or whether patients who
stop treatment retain the benefit they have received up to that point
For these reasons, it is not clear whether disease modifying treatments represent a cost
effective use of NHS resources
WHAT THIS STUDY ADDS
This two year interim analysis of the UK risk sharing scheme does not provide reliable
evidence on cost effectiveness of disease modifying treatments
Results are highly sensitive to how the baseline score and missing follow-up data are
handled
Longer more complete follow-up with additional reference datasets will be more informative
and less sensitive to short term fluctuations in disability
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